phm 27 (human)

Endogenous peptide product of human prepro-VIP and analog of porcine PHI-27; potent agonist for the human calcitonin receptor (EC50 = 11 nM). Transgenic mice expressing the human VIP/PHM 27 gene in pancreatic β-islets display enhanced glucose-induced insu

RFRP3(human) acetate(311309-27-0 free base) 是一种人类 GnIH 肽同源物，是一种有效的促性腺激素分泌抑制剂，可抑制 Ca2+ 动员。它是一种 NPFF1 受体激动剂，它抑制毛喉素诱导的 cAMP 产生，IC50 为 0.7 nM。

β-Endorphin (1-27) (human) acetate 存在于大脑垂体和下丘脑中，具有镇痛活性。 β-Endorphin (1-27) (human) acetate 是一种阿片受体激动剂，对 μ-阿片受体和 δ-阿片受体具有较好的亲和力。

PACAP (1-27), human, ovine, rat acetate (PACAP 1-27 acetate)(127317-03-7 free base) 是一种新的神经肽，最初从牛下丘脑中分离出来，也存在于人和大鼠中。

β-Endorphin (1-27) is an endogenous peptide that binds to μ-, δ-, and κ-opioid receptors (Kis = 5.31, 6.17, and 39.82 nM, respectively, in COS-1 cells expressing rat receptors). It binds to rat and mouse brain membrane preparations (IC50s = 1.1 and 5.7 nM, respectively) and induces chemotaxis of human monocytes in vitro when used at a concentration of 1 nM. Intracerebroventricular administration of β-endorphin (1-27) increases the latency to tail withdrawal in response to thermal stimulation in mice with a median antinociceptive dose (AD50) of 1,500 pmol per animal. It inhibits antinociception induced by β-endorphin in mice in response to thermal stimuli when administered at a dose of 65 pmol per animal. In rats, β-endorphin (1-27) does not affect drug-associated place preference when administered at doses up to 20 μg, i.c.v., but inhibits β-endorphin-induced place preference when administered at a dose of 10 μg per animal.

PHI 27 (human) trifluoroacetate 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T64705。

PACAP (6-27) (human, ovine, rat) 是一种对PACAP受体具有拮抗作用的化合物，可以抑制犬肾上腺对外源性VIP的反应。此化合物在心血管疾病和神经系统疾病研究中展现出应用潜力。

β-Endorphin (1-27) (human) 是一种 opioid 拮抗剂，与 μ-、δ- 及 κ-阿片受体结合，其 Kis 分别为 5.31、6.17 及 39.82 nM。该化合物还能够抑制由 β-Endorphin 及 etorphine 引起的痛觉消失。

Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, SK-N-MC, and T47D cells). In vivo, in newborn pigs, PACAP (6-27) (10 μM) inhibits vasodilation of pial arterioles induced by PACAP (1-27) and PACAP (1-38) . It also inhibits PACAP (1-27)-stimulated increases in plasma insulin and glucagon levels and pancreatic venous blood flow in dogs when administered locally to the pancreas at a dose of 500 μg.

PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA), an N-terminal fragment of PACAP-38, is an effective PACAP receptor antagonist with IC50 values of 3 nM for rat PAC1, 2 nM for rat VPAC1, and 5 nM for human VPAC2.

'(Met(O)27)-Glucagon (1-29) (human, rat, porcine) 为修饰版胰高血糖素。在大鼠肝细胞内，其促进葡萄糖合成的活性虽与天然胰高血糖素相似，但呈现出较低效率，暗示蛋氨酸对于胰高血糖素与其肝脏受体绑定具有关键性作用。'

GRP (14-27) (human, porcine, canine) 表现为铃蟾肽受体配体。其特异性结合受到 GTP 和 GDP 的抑制作用，但 GMP 对此无影响。

PACAP (1-27) (the N-terminal fragment of PACAP-38) is a novel neuropeptides originally isolated from bovine hypothalamus, also found in humans and rats.

Mini Gastrin I, human (TFA) is short for human Gastrin. It is a mother peptide composed of 5-17 amino acids.